Back to top
more

Roche Holding (RHHBY)

(Delayed Data from OTC)

$39.26 USD

39.26
1,211,621

+0.45 (1.16%)

Updated Nov 1, 2024 04:00 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck's (MRK) Pneumococcal Vaccine Vaxneuvance Gets EU Nod

by Zacks Equity Research

Merck's (MRK) Vaxneuvance includes pneumococcal serotypes 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.

Pfizer (PFE) COVID Pill Maintains Strong Efficacy, Stock Up

by Zacks Equity Research

Pfizer's (PFE) COVID-19 pill maintains a substantial reduction in hospitalizations and deaths observed during interim analysis last month in the final analysis of the study data.

Jazz Pharma (JAZZ) Begins Zepzelca Confirmatory Study for SCLC

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) and partner PharmaMar initiate a late-stage study to evaluate Zepzelca in metastatic SCLC. Data from the study will support full approval of the drug for the indication.

Aprea (APRE) Reports FDA Removal of Clinical Hold on Study

by Zacks Equity Research

The FDA removes its clinical hold on Aprea Therapeutics' (APRE) clinical study evaluating eprenetapopt combination study in lymphoid malignancies.

Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq

by Zacks Equity Research

Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.

Recursion (RXRX) Inks Neuroscience and Oncology Deal With Roche

by Zacks Equity Research

Recursion (RXRX) inks a collaboration with Roche to identify novel targets and advance medicines in areas of neuroscience and oncology indication. Shares rise.

Sanofi's (SNY) Filing for Rare Disease Drug Accepted by EMA

by Zacks Equity Research

The EMA accepts Sanofi's (SNY) regulatory submission seeking approval for olipudase alfa, a potential treatment for acid sphingomyelinase deficiency.

Roche (RHHBY) Actemra Gets CHMP Recommendation for COVID-19

by Zacks Equity Research

The CHMP recommends EU approval for Roche's (RHHBY) Actemra to treat patients with severe COVID-19.

Is Repligen (RGEN) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Repligen (RGEN) and Roche Holding AG (RHHBY) have performed compared to their sector so far this year.

Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

by Zacks Equity Research

Blueprint Medicines' (BPMC) Ayvakit, which has been approved to treat PDGFRA Exon 18 mutant gastrointestinal stromal tumors, has seen strong uptake since approval. However, stiff competition remains a headwind.

    Novartis (NVS) Highlights Growth Profile at its R&D Day

    by Zacks Equity Research

    Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.

    Jazz (JAZZ) Begins Zepzelca Combo Study for First-Line SCLC

    by Zacks Equity Research

    Jazz Pharmaceuticals (JAZZ) and partner Roche enrol the first patient in the phase III study to investigate the novel combination of Zepzelca and Tecentriq for small cell lung cancer.

    ImmunoGen (IMGN) Surges on Successful Ovarian Cancer Study

    by Zacks Equity Research

    ImmunoGen (IMGN) reports successful completion of a pivotal study evaluating its lead pipeline candidate as monotherapy in certain ovarian cancer patients previously treated with Avastin.

    4 Reasons Why You Should Add Sarepta (SRPT) to Your Portfolio

    by Zacks Equity Research

    Sarepta's (SRPT) stock creates a significant opportunity for investors on the back of solid demand for its commercialized drugs and steady progress with its key pipeline candidates.

    Kinjel Shah headshot

    Pharma Stock Roundup: FDA Nod to COVID Jab for All Adults, CHMP Nod to Shot for Kids

    by Kinjel Shah

    FDA authorizes booster doses of COVID-19 vaccines of Pfizer (PFE)/BioNTech (BNTX) and Moderna for all adults. CHMP gives nod to Pfizer/BioNTech's vaccine for young kids.

    Roche (RHHBY) Gets Approval for Gavreto for NSCLC in EU

    by Zacks Equity Research

    Roche (RHHBY) wins EC approval for Gavreto for the treatment of adults with RET fusion-positive advanced NSCLC.

    Atea (AVIR) Plunges on Termination of Collaboration With Roche

    by Zacks Equity Research

    Atea (AVIR) stock falls on termination of collaboration with Roche for the development of oral drug for the treatment of COVID-19.

    Biogen's (BIIB) Oral MS Drug Vumerity Gets Approval in Europe

    by Zacks Equity Research

    Biogen's (BIIB) Vumerity gets marketing authorization in Europe for the treatment of adults with relapsing-remitting multiple sclerosis.

    AstraZeneca (AZN), Moderna's Heart Failure Study Successful

    by Zacks Equity Research

    AstraZeneca (AZN) and Moderna are developing an mRNA-based therapeutic to treat heart failure in patients undergoing coronary artery bypass surgery.

    Regeneron (REGN), Roche Get EC Nod for COVID-19 Cocktail

    by Zacks Equity Research

    Regeneron (REGN) and partner Roche win the European Commission's approval for antibody cocktail to treat and prevent COVID-19.

    Biogen (BIIB) Up on New Data From Phase III Studies on Aduhelm

    by Zacks Equity Research

    Biogen's (BIIB) Aduhelm significantly lowers plasma p-tau-181, a pathological hallmark of Alzheimer's disease, in phase III studies.

    Regeneron (REGN)-Roche COVID-19 Cocktail Gets Positive CHMP Opinion

    by Zacks Equity Research

    Regeneron (REGN) and partner Roche obtain a positive opinion from CHMP for their antibody cocktail for the treatment of non-hospitalized patients with confirmed COVID-19 and to prevent the disease.

    AstraZeneca (AZN) Q3 Earnings Miss, Sales Beat, Stock Down

    by Zacks Equity Research

    AstraZeneca (AZN) surpasses third-quarter estimates for revenues while missing the same for earnings. The company retains 2021 guidance.

    Epizyme (EPZM) Q3 Loss Wider Than Expected, Revenues Up

    by Zacks Equity Research

    Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.

    Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales

    by Zacks Equity Research

    Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.